RNS Announcements

2023

04 January

Commercial and scientific update

2022

28 September

Unaudited Results to 30 June 2022

14 September

New commercialisation partner in Asia Pacific

14 June

Appointment of Chief Executive Officer

31 May

Launch of cholesterol reducing yoghurt

19 April

Change of registered office

01 April

Holding(s) in Company

31 March

Admission to trading on AQSE and first day of dealings

Latest RNS News

04 January 2023

Commercial and scientific update

28 September 2022

Unaudited Results to 30 June 2022

14 September 2022

New commercialisation partner in Asia Pacific

Latest Interview

ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023
www.proactiveinvestors.co.uk

Investor Alert